GlassScriptPhysician profile
Neil Morganstein
NPI 1568454080
$10,788.16
in general payments reported to CMS, 2019-2025
60 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $434 · 2021: $1,016 · 2022: $3,597 · 2023: $627 · 2024: $1,516 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,783 · Food and Beverage: $1,972 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,782.50 |
| Food and Beverage | $1,972.47 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,885.29 | 2019-2024 | |
| Janssen Global Services, LLC | $1,980.00 | 2025 | |
| Beigene, LTD. | $525.00 | 2021 | |
| Merck Sharp & Dohme LLC | $454.96 | 2019-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $307.76 | 2019-2024 | |
| Janssen Biotech, INC. | $302.01 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $241.17 | 2019-2025 | Reblozyl, Eliquis |
| Incyte Corporation | $222.49 | 2019-2025 | Jakafi |
| Pfizer INC. | $186.40 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $175.26 | 2019-2025 | Tagrisso |
| Secura Bio, INC. | $164.12 | 2019-2022 | |
| Amgen INC. | $155.06 | 2019-2022 | |
| Genentech USA, INC. | $138.87 | 2019-2025 | Polivy, Lunsumio, Venclexta |
| Celgene Corporation | $130.01 | 2020-2025 | Reblozyl |
| Lilly USA, LLC | $128.53 | 2019-2024 | Jaypirca, Retevmo |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Morganstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.